The Valley Desk

NCT05287113 · Interventional trial

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Overall registry status Completed

Phase 2

Conditions Head and Neck Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov